Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJ9XCO)

Drug Name

CCX-140 Drug Info

Synonyms

CCX-140-B; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease), ChemoCentryx; CCR2 receptor antagonist (inflammation/multiple sclerosis/metabolic disease/chronic kidney disease), ChemoCentryx

Indication

Disease Entry	ICD 11	Status	REF
Diabetic nephropathy	GB61.Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 25134303
CAS Number: CAS 1100318-47-5
TTD Drug ID: DMJ9XCO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-C chemokine receptor type 2 (CCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cenicriviroc	DM4V8WF	Human immunodeficiency virus infection	1C62	Phase 2	[3]
MLN1202	DM24SOL	Metastatic cancer	2D50-2E2Z	Phase 2	[4]
BMS-813160	DMKY638	Diabetic nephropathy	GB61.Z	Phase 2	[5]
AZD-2423	DMF34UY	Chronic obstructive pulmonary disease	CA22	Phase 2	[6]
CCX872	DMPVAUT	Pancreatic tumour	2C10	Phase 2	[7]
MK-0812	DMRT8K4	Multiple sclerosis	8A40	Phase 2	[8]
Aminoguanidine	DMJQDUC	Diabetic retinopathy	9B71.0	Phase 1	[9]
TAK-202	DMVYEFZ	Melanoma	2C30	Phase 1	[10]
OPL-CCL2-LPM	DM3HOUX	Arthritis	FA20	Phase 1	[11]
CNTX-6970	DMCOJM7	Inflammatory pain	MG30.42	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 2 (CCR2)	TTFZYTO	CCR2_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018498)
2	Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
5	A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
6	CA patent application no. 841416, Method of selecting therapeutic indications.
7	Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
8	Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
9	Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303.
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)